tiprankstipranks
Trending News
More News >

MedinCell initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of MedinCell (MDCLF) with an Outperform rating and no price target The French biotech company specializing in long-acting injectable formulation technology earns revenue through royalties on worldwide net sales of partnered drugs as well as through licensing fees and milestones and has become “an increasingly popular partner-of-choice” for big pharma companies, the analyst tells investors. Currently partnered with Teva (TEVA) on their LAI atypical antipsychotics used in schizophrenia, Uzedy royalties will get them to profitability in 2027, but the main focus is on LAI olanzapine, which is expected to launch into a market with essentially zero competition in 2026, if approved, the analyst tells investors.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1